Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard Total Bond Market Index Fund ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.43 (market cap $29.60B), while Vanguard Total Bond Market Index Fund ETF trades at $72.28. Which is the better fit depends on your goals.
| ALNY | BND | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $75.17 |
52-Week Low | $205.48 | $72.15 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
BND trades at $72.34, up 0.26% today, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights focus on bond ETF inflows and comparisons with peers like AGG, while institutional activity includes mixed holdings adjustments by wealth managers.
The outlook remains cautious due to technical weakness and macroeconomic sensitivity to Treasury yields and inflation data. Risks include interest rate volatility and competitive pressures from other fixed-income funds. Analyst sentiment is neutral, with no clear bullish catalysts in the near term, emphasizing income stability over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
